Suppr超能文献

一系列双位点配体对 A 腺苷受体的变构拮抗作用。

Allosteric Antagonism of the A Adenosine Receptor by a Series of Bitopic Ligands.

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Cells. 2020 May 12;9(5):1200. doi: 10.3390/cells9051200.

Abstract

Allosteric antagonism by bitopic ligands, as reported for many receptors, is a distinct modulatory mechanism. Although several bitopic A adenosine receptor (AAR) ligand classes were reported as pharmacological tools, their receptor binding and functional antagonism patterns, i.e., allosteric or competitive, were not well characterized. Therefore, here we systematically characterized AAR binding and functional antagonism of two distinct antagonist chemical classes. i.e., fluorescent conjugates of xanthine amine congener (XAC) and SCH442416. Bitopic ligands were potent, weak, competitive or allosteric, based on the combination of pharmacophore, linker and fluorophore. Among antagonists tested, XAC, XAC245, XAC488, SCH442416, MRS7352 showed K binding values consistent with K values from functional antagonism. Interestingly, MRS7396, XAC-X-BY630 (XAC630) and 5-(,-hexamethylene)amiloride (HMA) were 9-100 times weaker in displacing fluorescent MRS7416 binding than radioligand binding. XAC245, XAC630, MRS7396, MRS7416 and MRS7322 behaved as allosteric AAR antagonists, whereas XAC488 and MRS7395 antagonized competitively. Schild analysis showed antagonism slopes of 0.42 and 0.47 for MRS7396 and XAC630, respectively. Allosteric antagonists HMA and MRS7396 were more potent in displacing [H]ZM241385 binding than MRS7416 binding. Sodium site D52N mutation increased and decreased affinity of HMA and MRS7396, respectively, suggesting possible preference for different AAR conformations. The allosteric binding properties of some bitopic ligands were rationalized and analyzed using the Hall two-state allosteric model. Thus, fluorophore tethering to an orthosteric ligand is not neutral pharmacologically and may confer unexpected properties to the conjugate.

摘要

变构拮抗剂通过双位配体作用,正如许多受体所报告的那样,是一种独特的调节机制。尽管已经报道了几种双位 A 腺苷受体 (AAR) 配体类别作为药理学工具,但它们的受体结合和功能拮抗模式,即变构或竞争性,尚未得到很好的表征。因此,在这里我们系统地研究了两种不同的拮抗剂化学类别(黄嘌呤胺同系物 (XAC) 和 SCH442416 的荧光缀合物)对 AAR 的结合和功能拮抗作用。双位配体是基于药效团、连接子和荧光团的组合而具有强效、弱效、竞争性或变构性。在所测试的拮抗剂中,XAC、XAC245、XAC488、SCH442416 和 MRS7352 的结合 K 值与功能拮抗作用的 K 值一致。有趣的是,MRS7396、XAC-X-BY630(XAC630)和 5-(-,-六亚甲基)阿米洛利(HMA)在置换荧光 MRS7416 结合方面比放射性配体结合弱 9-100 倍。XAC245、XAC630、MRS7396、MRS7416 和 MRS7322 表现为 AAR 的变构拮抗剂,而 XAC488 和 MRS7395 竞争性拮抗。Schild 分析显示 MRS7396 和 XAC630 的拮抗斜率分别为 0.42 和 0.47。变构拮抗剂 HMA 和 MRS7396 比 MRS7416 更能有效地置换 [H]ZM241385 结合。钠离子位点 D52N 突变分别增加和降低 HMA 和 MRS7396 的亲和力,表明可能对不同的 AAR 构象有偏好。一些双位配体的变构结合特性使用 Hall 双态变构模型进行了合理化和分析。因此,将荧光团连接到正位配体上在药理学上并不是中性的,并且可能会为缀合物赋予意想不到的特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f8e2/7290864/382264f1b74b/cells-09-01200-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验